Cyclic Peptides That Block Cancer Cell Division by Targeting CDK2 Recruitment
Designed cyclic peptides inhibited CDK2 by targeting its substrate recruitment site rather than the catalytic site, selectively inducing apoptosis in tumor cells through the E2F pathway — a novel cancer-selective mechanism.
Quick Facts
What This Study Found
Cyclic peptides targeting CDK2's substrate recruitment site (not catalytic site) selectively induced tumor cell apoptosis through the E2F pathway, with crystal structures confirming the novel binding mechanism.
Key Numbers
How They Did This
In-vitro study. Cyclic peptide design, synthesis, and testing for CDK2 substrate recruitment inhibition. Cancer cell apoptosis measured. Crystal structures of peptide-CDK2 complexes determined.
Why This Research Matters
Cancer-selective cell killing is the holy grail of oncology. Targeting CDK2's substrate site achieves selectivity that conventional kinase inhibitors (which target the active site shared by many kinases) cannot.
The Bigger Picture
Targeting protein-protein interaction sites rather than catalytic sites is an emerging drug design paradigm. These cyclic CDK2 inhibitors exemplify this approach for cancer therapy.
What This Study Doesn't Tell Us
In-vitro cancer cell studies. In-vivo efficacy and pharmacokinetics not assessed. Cyclic peptide drug delivery remains challenging.
Questions This Raises
- ?Can these cyclic peptides achieve sufficient oral bioavailability?
- ?Would this approach work for other cancer-driving CDKs?
- ?How does the selectivity profile compare to clinical CDK4/6 inhibitors?
Trust & Context
- Key Stat:
- Substrate site = selectivity Targeting CDK2's substrate recruitment groove instead of its active site achieved cancer cell selectivity — a design principle for tumor-specific drugs
- Evidence Grade:
- Preliminary in-vitro evidence with structural validation (crystal structures) confirming the novel binding mechanism.
- Study Age:
- Published in 2004. CDK-targeting cancer drugs have since reached clinical use (palbociclib, ribociclib), validating the CDK target.
- Original Title:
- Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
- Published In:
- Organic & biomolecular chemistry, 2(19), 2735-41 (2004)
- Authors:
- Andrews, Martin J I, McInnes, Campbell, Kontopidis, George, Innes, Lorraine, Cowan, Angela, Plater, Andy, Fischer, Peter M
- Database ID:
- RPEP-00881
Evidence Hierarchy
Frequently Asked Questions
How is this different from regular cancer drugs?
Most kinase inhibitors block the active site, which is similar across many kinases (causing side effects). These cyclic peptides target a unique substrate-grabbing groove, achieving cancer selectivity.
Could this become a cancer treatment?
The approach is sound and validated by crystal structures. Converting these peptides into stable, deliverable drugs is the remaining challenge.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00881APA
Andrews, Martin J I; McInnes, Campbell; Kontopidis, George; Innes, Lorraine; Cowan, Angela; Plater, Andy; Fischer, Peter M. (2004). Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.. Organic & biomolecular chemistry, 2(19), 2735-41.
MLA
Andrews, Martin J I, et al. "Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.." Organic & biomolecular chemistry, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Design, synthesis, biological activity and structural analys..." RPEP-00881. Retrieved from https://rethinkpeptides.com/research/andrews-2004-design-synthesis-biological-activity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.